Single-dose NEPA versus 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with risk factors receiving moderately emetogenic chemotherapy (MEC)

被引：1
|
作者：
Zelek, L. [1 ]
Debourdeau, P. [2 ]
Bourgeois, H. [3 ]
Wagner, J. P. [4 ]
Brocard, F. [5 ]
Lefeuvre-Plesse, C. [6 ]
Chauffert, B. [7 ]
Leheurteur, M. [8 ]
Bachet, J-B. [9 ]
Simon, H. [10 ]
Mayeur, D. [11 ]
Jovenin, N. [12 ]
Scotte, F. [13 ]
机构：
[1] Hop Avicenne, AP HP, Med Oncol, Bobigny, France
[2] Inst St Catherine, Oncol Support Care, Avignon, France
[3] Clin Victor Hugo, Med Oncol, Le Mans, France
[4] Inst Andree Dutreix & Clin Flandre, Res Innovat & External Commun, Dunkerque, France
[5] Polyclin Gentilly, Med Oncol, Nancy, France
[6] Ctr Eugene Marquis, Med Oncol, Rennes, France
[7] CHU Amiens Picardie Site Nord, Med Oncol Dept, Amiens, France
[8] Ctr Henri Becquerel, Med Oncol, Rouen, France
[9] Grp Hosp Pitie Salpetriere, Serv Hepatogastroenterol, Paris, France
[10] CHU Morvan, Inst Cancerol & Hematol, Brest, France
[11] Ctr George Francois Leclerc, Med Oncol, Dijon, France
[12] Inst Canc Courlancy Reims, Med Oncol, Reims, France
[13] Gustave Roussy, Interdisciplinary Canc Course Dept, Canc Ctr, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1672P
引用
收藏
页码：S1175 / S1175
页数：1
相关论文
共 50 条
  • [1] Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Zelek, Laurent
    Navari, Rudolph
    Aapro, Matti
    Scotte, Florian
    CANCER MEDICINE, 2023, 12 (15): : 15769 - 15776
  • [2] Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated with Moderately Emetogenic (MEC) Chemotherapy in Patients with Breast Cancer
    Webb, T.
    Hardwick, J.
    Carides, A. D.
    Street, J. C.
    CANCER RESEARCH, 2009, 69 (24) : 575S - 576S
  • [3] A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
    Zelek, Laurent
    Debourdeau, Philippe
    Bourgeois, Hugues
    Wagner, Jean Philippe
    Brocard, Fabien
    Lefeuvre-Plesse, Claudia
    Chauffert, Bruno
    Leheurteur, Marianne
    Bachet, Jean-Baptiste
    Simon, Helene
    Mayeur, Didier
    Scotte, Florian
    ONCOLOGIST, 2021, 26 (10): : E1870 - E1879
  • [4] Efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)
    Aapro, M.
    Rossi, G.
    Rizzi, G.
    Borroni, M. E.
    Lorusso, V.
    Karthaus, M.
    Grunberg, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S266 - S266
  • [5] Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gastrointestinal cancers receiving moderately emetogenic chemotherapy regimens
    Cindy, Weinstein
    Karin, Jordan
    Stuart, Green
    Saleem, Khanani
    Elizabeth, Beckford-Brathwaite
    Waldimir, Vallejos
    Annpey, Pong
    Stephen, Noga
    Bernardo, Rapoport
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancers receiving moderately emetogenic chemotherapy regimens
    Weinstein, C.
    Jordan, K.
    Green, S.
    Khanani, S.
    Beckford-Brathwaite, E.
    Vallejos, W.
    Pong, A.
    Noga, S. J.
    Rapoport, B. L.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 161 - 162
  • [7] Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer receiving moderately emetogenic chemotherapy regimens
    Weinstein, Cindy
    Jordan, Karin
    Green, Stuart
    Khanani, Saleem
    Beckford-Brathwaite, Elizabeth
    Vallejos, Waldimir
    Pong, Annpey
    Noga, Stephen J.
    Rapoport, Bernardo L.
    CANCER RESEARCH, 2018, 78 (04)
  • [8] Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Takako Inoue
    Madoka Kimura
    Junji Uchida
    Kazumi Nishino
    Toru Kumagai
    Junko Taniguchi
    Fumio Imamura
    International Journal of Clinical Oncology, 2017, 22 : 600 - 604
  • [9] Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Inoue, Takako
    Kimura, Madoka
    Uchida, Junji
    Nishino, Kazumi
    Kumagai, Toru
    Taniguchi, Junko
    Imamura, Fumio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (03) : 600 - 604
  • [10] A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
    Zhang, L.
    Lu, S.
    Feng, J.
    Dechaphunkul, A.
    Chang, J.
    Wang, D.
    Chessari, S.
    Lanzarotti, C.
    Jordan, K.
    Aapro, M.
    ANNALS OF ONCOLOGY, 2018, 29 (02) : 452 - 458
12345